Tag: gm1 gangliosidosis market analysis

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

GM1 Gangliosidosis Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for gm1 gangliosidosis experienced substantial expansion recently, projected to increase from $0.57 billion in 2025 to $0.63 billion in 2026, reflecting an 11.1% compound annual growth rate. Historical drivers behind this market growth include dedicated research into rare diseases, enhanced capabilities in identifying enzyme deficiencies, significant progress in genetic diagnostic technologies, the availability of specialized pediatric care within hospitals, and the foundational outcomes from initial clinical investigations.

The global market for gm1 gangliosidosis is poised for significant expansion, projecting a valuation of $0.96 billion by 2030 with a compound annual growth rate of 10.8%. This anticipated surge is propelled by several key factors, including advancements in gene therapy development and the supportive framework of orphan drug incentives. Furthermore, enhanced diagnostic capabilities, a growing voice among patient advocacy groups, and increased investment in biotechnology are contributing to this upward trajectory. Emerging trends that will shape the market during the forecast period encompass a heightened emphasis on developing treatments for rare diseases, intensified research efforts in gene therapy, broader adoption of enzyme replacement therapies, expanded genetic screening programs for newborns, and a notable increase in clinical trial initiatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

GM1 Gangliosidosis Market Opportunity Drivers: What Is Creating New Revenue Potential?

A significant driver for the expansion of the GM1 gangliosidosis market is the escalating utilization of gene therapy, a revolutionary medical approach that aims to address diseases by modifying or substituting genes within an individual’s cells. This surge in gene therapy adoption stems from progress in genetic understanding, enhanced therapeutic results for previously intractable ailments, and increasing governmental endorsement of novel treatment strategies. Specifically concerning GM1 gangliosidosis, gene therapy entails introducing a functional version of the faulty GLB1 gene into patients’ cells, thereby reinstating the activity of the ß-galactosidase enzyme and mitigating the accumulation of harmful substances. A compelling indicator of this trend is the report from the American Society of Gene & Cell Therapy in January 2024, which noted a 10% increase in the number of gene therapies progressing to Phase III during the fourth quarter of 2023, marking the first such uptick since the third quarter of 2022, thus underscoring gene therapy’s pivotal role in propelling the GM1 gangliosidosis market forward.

GM1 Gangliosidosis Market Segmentation And Category Breakdown

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

GM1 Gangliosidosis Market Innovation Trends Driving Future Development

In the competitive landscape of the GM1 gangliosidosis market, leading entities are prioritizing strategic alliances to solidify their standing. These collaborations are instrumental in propelling gene therapy advancements, as they synergize specialized knowledge, pooled resources, and innovative technologies to expedite the trajectory from initial research to clinical validation and eventual market introduction. A notable instance occurred in October 2024 when GEMMA Biotherapeutics Inc., a US-based player in the biotechnology sector, joined forces with Oswaldo Cruz Foundation (Fiocruz), a prominent Brazilian health research organization. This partnership is geared towards the development of gene therapies targeting rare conditions, inclusive of GM1 gangliosidosis. The terms of this alliance stipulate potential funding up to $100 million from Fiocruz, designated for clinical investigation and production, with the ultimate goal of integrating these cutting-edge treatments into Brazil’s public healthcare infrastructure. This cooperative effort is designed to facilitate technology transfer and democratize access to therapies that have historically been confined to individuals with greater financial means.

GM1 Gangliosidosis Market Competitive Analysis Of Major Industry Participants

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Access The Complete GM1 Gangliosidosis Market Report:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

GM1 Gangliosidosis Market Largest Region By Revenue And Market Share

North Americawas the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

GM1 Gangliosidosis Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for gm1 gangliosidosis experienced substantial expansion recently, projected to increase from $0.57 billion in 2025 to $0.63 billion in 2026, reflecting an 11.1% compound annual growth rate. Historical drivers behind this market growth include dedicated research into rare diseases, enhanced capabilities in identifying enzyme deficiencies, significant progress in genetic diagnostic technologies, the availability of specialized pediatric care within hospitals, and the foundational outcomes from initial clinical investigations.

The global market for gm1 gangliosidosis is poised for significant expansion, projecting a valuation of $0.96 billion by 2030 with a compound annual growth rate of 10.8%. This anticipated surge is propelled by several key factors, including advancements in gene therapy development and the supportive framework of orphan drug incentives. Furthermore, enhanced diagnostic capabilities, a growing voice among patient advocacy groups, and increased investment in biotechnology are contributing to this upward trajectory. Emerging trends that will shape the market during the forecast period encompass a heightened emphasis on developing treatments for rare diseases, intensified research efforts in gene therapy, broader adoption of enzyme replacement therapies, expanded genetic screening programs for newborns, and a notable increase in clinical trial initiatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

GM1 Gangliosidosis Market Opportunity Drivers: What Is Creating New Revenue Potential?

A significant driver for the expansion of the GM1 gangliosidosis market is the escalating utilization of gene therapy, a revolutionary medical approach that aims to address diseases by modifying or substituting genes within an individual’s cells. This surge in gene therapy adoption stems from progress in genetic understanding, enhanced therapeutic results for previously intractable ailments, and increasing governmental endorsement of novel treatment strategies. Specifically concerning GM1 gangliosidosis, gene therapy entails introducing a functional version of the faulty GLB1 gene into patients’ cells, thereby reinstating the activity of the ß-galactosidase enzyme and mitigating the accumulation of harmful substances. A compelling indicator of this trend is the report from the American Society of Gene & Cell Therapy in January 2024, which noted a 10% increase in the number of gene therapies progressing to Phase III during the fourth quarter of 2023, marking the first such uptick since the third quarter of 2022, thus underscoring gene therapy’s pivotal role in propelling the GM1 gangliosidosis market forward.

GM1 Gangliosidosis Market Segmentation And Category Breakdown

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

GM1 Gangliosidosis Market Innovation Trends Driving Future Development

In the competitive landscape of the GM1 gangliosidosis market, leading entities are prioritizing strategic alliances to solidify their standing. These collaborations are instrumental in propelling gene therapy advancements, as they synergize specialized knowledge, pooled resources, and innovative technologies to expedite the trajectory from initial research to clinical validation and eventual market introduction. A notable instance occurred in October 2024 when GEMMA Biotherapeutics Inc., a US-based player in the biotechnology sector, joined forces with Oswaldo Cruz Foundation (Fiocruz), a prominent Brazilian health research organization. This partnership is geared towards the development of gene therapies targeting rare conditions, inclusive of GM1 gangliosidosis. The terms of this alliance stipulate potential funding up to $100 million from Fiocruz, designated for clinical investigation and production, with the ultimate goal of integrating these cutting-edge treatments into Brazil’s public healthcare infrastructure. This cooperative effort is designed to facilitate technology transfer and democratize access to therapies that have historically been confined to individuals with greater financial means.

GM1 Gangliosidosis Market Competitive Analysis Of Major Industry Participants

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Access The Complete GM1 Gangliosidosis Market Report:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

GM1 Gangliosidosis Market Largest Region By Revenue And Market Share

North Americawas the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

GM1 Gangliosidosis Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for gm1 gangliosidosis experienced substantial expansion recently, projected to increase from $0.57 billion in 2025 to $0.63 billion in 2026, reflecting an 11.1% compound annual growth rate. Historical drivers behind this market growth include dedicated research into rare diseases, enhanced capabilities in identifying enzyme deficiencies, significant progress in genetic diagnostic technologies, the availability of specialized pediatric care within hospitals, and the foundational outcomes from initial clinical investigations.

The global market for gm1 gangliosidosis is poised for significant expansion, projecting a valuation of $0.96 billion by 2030 with a compound annual growth rate of 10.8%. This anticipated surge is propelled by several key factors, including advancements in gene therapy development and the supportive framework of orphan drug incentives. Furthermore, enhanced diagnostic capabilities, a growing voice among patient advocacy groups, and increased investment in biotechnology are contributing to this upward trajectory. Emerging trends that will shape the market during the forecast period encompass a heightened emphasis on developing treatments for rare diseases, intensified research efforts in gene therapy, broader adoption of enzyme replacement therapies, expanded genetic screening programs for newborns, and a notable increase in clinical trial initiatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

GM1 Gangliosidosis Market Opportunity Drivers: What Is Creating New Revenue Potential?

A significant driver for the expansion of the GM1 gangliosidosis market is the escalating utilization of gene therapy, a revolutionary medical approach that aims to address diseases by modifying or substituting genes within an individual’s cells. This surge in gene therapy adoption stems from progress in genetic understanding, enhanced therapeutic results for previously intractable ailments, and increasing governmental endorsement of novel treatment strategies. Specifically concerning GM1 gangliosidosis, gene therapy entails introducing a functional version of the faulty GLB1 gene into patients’ cells, thereby reinstating the activity of the ß-galactosidase enzyme and mitigating the accumulation of harmful substances. A compelling indicator of this trend is the report from the American Society of Gene & Cell Therapy in January 2024, which noted a 10% increase in the number of gene therapies progressing to Phase III during the fourth quarter of 2023, marking the first such uptick since the third quarter of 2022, thus underscoring gene therapy’s pivotal role in propelling the GM1 gangliosidosis market forward.

GM1 Gangliosidosis Market Segmentation And Category Breakdown

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

GM1 Gangliosidosis Market Innovation Trends Driving Future Development

In the competitive landscape of the GM1 gangliosidosis market, leading entities are prioritizing strategic alliances to solidify their standing. These collaborations are instrumental in propelling gene therapy advancements, as they synergize specialized knowledge, pooled resources, and innovative technologies to expedite the trajectory from initial research to clinical validation and eventual market introduction. A notable instance occurred in October 2024 when GEMMA Biotherapeutics Inc., a US-based player in the biotechnology sector, joined forces with Oswaldo Cruz Foundation (Fiocruz), a prominent Brazilian health research organization. This partnership is geared towards the development of gene therapies targeting rare conditions, inclusive of GM1 gangliosidosis. The terms of this alliance stipulate potential funding up to $100 million from Fiocruz, designated for clinical investigation and production, with the ultimate goal of integrating these cutting-edge treatments into Brazil’s public healthcare infrastructure. This cooperative effort is designed to facilitate technology transfer and democratize access to therapies that have historically been confined to individuals with greater financial means.

GM1 Gangliosidosis Market Competitive Analysis Of Major Industry Participants

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Access The Complete GM1 Gangliosidosis Market Report:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

GM1 Gangliosidosis Market Largest Region By Revenue And Market Share

North Americawas the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The GM1 Gangliosidosis Market Expected To Change From 2026 To 2030?

The gm1 gangliosidosis market has experienced substantial expansion in recent years. It is projected to expand from $0.57 billion in 2025 to $0.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to key factors such as rare disease research initiatives, the identification of enzyme deficiencies, advancements in genetic diagnostics, hospital-based pediatric care, and initial clinical studies.

The gm1 gangliosidosis market is projected to experience substantial growth over the coming years. It is anticipated to expand to $0.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This expansion during the forecast period can be attributed to the advancement of the gene therapy pipeline, orphan drug incentives, more effective diagnostic screening, heightened patient advocacy, and increased biotechnology funding. Significant trends for this period include an intensified focus on developing drugs for rare diseases, greater research into gene therapy, the expanding application of enzyme replacement therapies, the broadening of newborn genetic screening, and a rise in clinical trial activity.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Which Important Drivers Are Guiding The GM1 Gangliosidosis Market Growth?

The rising acceptance of gene therapy is anticipated to stimulate the expansion of the GM1 gangliosidosis market. Gene therapy represents a medical intervention designed to modify or replace genes within an individual’s cells to either treat existing conditions or prevent their onset. The increasing adoption of this therapy is driven by advancements in genetic research, enhanced treatment outcomes for ailments previously deemed untreatable, and growing regulatory encouragement for innovative therapeutic approaches. For GM1 gangliosidosis, gene therapy functions by introducing a working version of the defective GLB1 gene into patient cells, aiming to reactivate β-galactosidase enzyme activity and thereby lessen the harmful buildup of substrates. For example, in January 2024, data from the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated that the number of gene therapies in Phase III increased by 10% in Q4 2023 compared to the preceding quarter, signifying the first such rise since Q3 2022. Therefore, the expanding use of gene therapy is a key factor propelling the growth of the GM1 gangliosidosis market.

How Is The GM1 Gangliosidosis Market Categorized Across Its Segment Groups?

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

What Trends Are Influencing The Evolution Of The GM1 Gangliosidosis Market?

Leading companies active in the GM1 gangliosidosis market are concentrating on strategic alliances to secure their market position. These strategic partnerships are crucial for progressing gene therapy development by combining shared expertise, resources, and technologies to accelerate research, clinical trials, and eventual commercialization. For example, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology firm, joined forces with the Oswaldo Cruz Foundation (Fiocruz), a health research institution from Brazil, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The arrangement includes up to $100 million in funding from Fiocruz for clinical research and manufacturing, intended to make these advanced therapies accessible through Brazil’s public healthcare system. This cooperative effort underscores technology transfer and aims to widen access to treatments that were previously limited to wealthier populations.

Which Firms Are Influencing Competition In The GM1 Gangliosidosis Market?

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Get The Full GM1 Gangliosidosis Market Report:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Which Region Has The Greatest Market Share In The GM1 Gangliosidosis Market?

North America was the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized GM1 Gangliosidosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2026, By The Business Research Company

Glycol Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycol-global-market-report

Alpha Mannosidosis Market 2026

https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market

Paraganglioma Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The GM1 Gangliosidosis Market Over The 2026–2030 Period?

The market for gm1 gangliosidosis has experienced rapid expansion in recent years. It is projected to increase from $0.57 billion in 2025 to $0.63 billion in 2026, at a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to elements such as rare disease research initiatives, the identification of enzyme deficiencies, advancements in genetic diagnostics, hospital-based pediatric care, and early clinical studies.

The gm1 gangliosidosis market is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $0.96 billion, demonstrating a compound annual growth rate (CAGR) of 10.8%. This anticipated growth during the forecast period is primarily driven by factors such as the expansion of the gene therapy pipeline, incentives for orphan drugs, advancements in diagnostic screening, heightened patient advocacy, and increased biotechnology funding. Key developments expected within the forecast timeframe encompass an escalating emphasis on developing drugs for rare diseases, intensified research into gene therapy, broader adoption of enzyme replacement therapies, wider implementation of newborn genetic screening, and a surge in clinical trial undertakings.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

Which Economic Or Industry Drivers Are Impacting The GM1 Gangliosidosis Market?

The expanding integration of gene therapy is projected to stimulate the growth of the GM1 gangliosidosis market moving forward. Gene therapy is a medical intervention that involves altering or replacing genes within a person’s cells to manage or prevent diseases. The increasing uptake of gene therapy is propelled by advances in genetic research, improved patient outcomes for conditions that were previously untreatable, and strengthening regulatory support for innovative treatments. For GM1 gangliosidosis, gene therapy works by delivering a functional copy of the defective gene (GLB1) to patient cells, aiming to restore ß-galactosidase enzyme activity and reduce the buildup of toxic substrates. For example, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization, reported that in Q4 2023, the number of gene therapies in Phase III increased by 10% compared to the prior quarter, marking the first rise since Q3 2022. Therefore, the growing adoption of gene therapy is driving the expansion of the GM1 gangliosidosis market.

How Is The GM1 Gangliosidosis Market Segmented Across Key Categories?

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

Which Trends Are Impacting The Growth Of The GM1 Gangliosidosis Market?

Leading companies active in the GM1 gangliosidosis market are prioritizing strategic alliances to secure their market presence. Strategic partnerships are essential for advancing gene therapy development by integrating expertise, resources, and technologies to accelerate research, clinical trials, and commercialization. For example, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, formed a partnership with the Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The agreement entails up to $100 million in funding from Fiocruz for clinical research and manufacturing, intending to make these advanced therapies accessible through Brazil’s public healthcare system. This collaboration underscores technology transfer and aims to democratize access to treatments that were previously restricted to higher-income populations.

Who Are The Dominant Players Shaping The GM1 Gangliosidosis Market Landscape?

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Read the full gm1 gangliosidosis market report here:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

What Are The Top-Performing Regions Within The GM1 Gangliosidosis Market?

North America was the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored GM1 Gangliosidosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp

Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2026, By The Business Research Company

Glycomic Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycol Global Market Report

https://www.thebusinessresearchcompany.com/report/glycol-global-market-report

Glyphosate Global Market Report

https://www.thebusinessresearchcompany.com/report/glyphosate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model